ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023
Improving generalizability and study design of Alzheimer's disease cohort studies in the United States by including under-represented populations.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Community engagement, recruitment, and retention of minoritized participants in Alzheimer's disease and related dementia research: A systematic review of disparities.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- Association Between the Genetic Risk for Attention-Deficit/Hyperactivity Disorder and Cognitive Function in Older Age: The MYHAT Population-Based Study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2026Article
- The BEYONDD Pilot Study: A Decentralized Community-Engaged Research Framework for Multimodal Characterization of Neurodegenerative Risk in a Multi-Ethnic, Midlife Cohort with Subjective Cognitive or Behavioral Complaints.medRxiv : the preprint server for health sciences · 2026Article
- Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Feasibility and validity of using self-collected capillary blood using Tasso+ for measuring Alzheimer's Disease plasma-based biomarkers among underrepresented populations.medRxiv : the preprint server for health sciences · 2026Article
- Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study.Journal of asthma and allergy · 2026Article
- The Population Neuroscience-Dementia Syndemics Framework to better understand global sex and gender-based risk in low- and middle-income countries.Nature aging · 2026Review
- Comprehensive methodology for sample enrichment in EEG biomarker studies for Alzheimer's risk classification.PloS one · 2026Article
- Factors associated with age at tau pathology onset and time from tau onset to dementia in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Association of Alzheimer's Disease Polygenic Risk Score with Concussion Severity and Recovery Metrics.Sports medicine (Auckland, N.Z.) · 2025Article
- Pathways to Racial/Ethnic Inequalities in Dementia.Annual review of clinical psychology · 2025Review
- The POINTER Imaging baseline cohort: Associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- The ADNI Administrative Core: Ensuring ADNI's success and informing future AD clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Dementia risk scores, apolipoprotein E, and risk of Alzheimer's disease: One size does not fit all.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- A short version of the Everyday Cognition scale can predict clinical progression and cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The Health Equity Scholars Program: Fostering Culturally Competent and Successful Independent Investigators in Alzheimer's Disease and Related Dementia Research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The Alzheimer's Disease Neuroimaging Initiative-4 (ADNI-4) Engagement Core: A culturally informed, community-engaged research (CI-CER) model to advance brain health equity.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 2 countries.
Funding
Abstract
The poor generalizability of clinical research data due to the enrollment of highly educated, non-Latinx White participants hampers the development of therapies for Alzheimer's disease (AD). Black and Latinx older adults have a greater risk for dementia, yet it is unclear how health-care disparities and sociocultural factors influence potential AD therapies and prognosis. Low enrollment of under-represented populations may be attributable to several factors including greater exclusion due to higher rates of comorbidities, lower access to AD clinics, and the legacy of unethical treatment in medical research. This perspective outlines solutions tested in the Brain Health Registry (BHR) and the Alzheimer's Disease Neuroimaging Initiative (ADNI), including culturally-informed digital research methods, community-engaged research strategies, leadership from under-represented communities, and the reduction of exclusion criteria based on comorbidities. Our successes demonstrate that it is possible to increase the inclusion and engagement of under-represented populations into US-based clinical studies, thereby increasing the generalizability of their results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.